Xerava (Eravacycline)

Xerava is a tetracycline class antibacterial used for the treatment of complicated intra-abdominal infections in patients aged 18 years and older. 

To scale down the development of drug-resistant bacteria and sustain the effectiveness of Eravacycline and other antibacterial medicines, Eravacycline needs to be used only to treat/prevent infections that are demonstrated or firmly suspected to be caused by susceptible bacteria. When culture and susceptibility deets are available, they needs to be considered in selecting or modifying antibacterial therapy. In unavailability of such findings, local epidemiology and susceptibility patterns may help contribute to the empiric selection of therapy. 

Limitations of Use: This medicinal product is not for those with complicated urinary tract infections (cUTI). 

Recommended Dosage: The recommended dose regimen of Xerava injection is 1 mg/kg every 12 hours. Dosage of Xerava is administered intravenously over approximately 60 minutes every 12 hours.

The recommended time-span of treatment with Xerava for cIAI is 4-14 days. The time-span of therapy should be guided by the severity and location of infection and the patient’s clinical response.

Dosage Modifications in those with Hepatic Impairment: In those with severe hepatic impairment (Child Pugh C), administer Xerava 1 mg per kg every 12 hours on Day 1’st followed by Xerava 1 mg per kg every 24 hours starting on Day 2’nd for a total duration of 4-14 days. Dosage adjustment is not warranted in those with mild-moderate hepatic impairment (Child Pugh A/B). 

• It is not advisable to use Eravacycline in patients with any known hypersensitivity to this medicine, tetracycline-class antibacterial medications, or to any of the excipients. 
• Life-threatening hypersensitivity (anaphylactic) reactions may occur with Xerava 50 mg. Eravacycline is structurally identical to other tetracycline-class antibacterial medicines and need to be avoided in those with known hypersensitivity to tetracycline-class antibacterial medicines. Discontinue this therapy if an allergic reaction appears.
• The use of Eravacycline during the 2’nd and 3’rd trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth. Advise patient of the potential risk to the fetus if this medicine is used during the 2’nd or 3’rd trimester of pregnancy. 
• Clostridium difficile associated diarrhea (CDAD) may occur with use of around all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. If CDAD is occurred or confirmed, ongoing antibacterial medicine use not directed against C. difficile may need to be interrupted. Apt fluid and electrolyte management, protein supplementation, antibacterial medicine treatment of C. difficile, and surgical assessment should be instituted as clinically required.
• Xerava injection is structurally identical to tetracycline-class antibacterial medicines and may have identical side effects. Side effects including pseudotumor cerebri, photosensitivity, and anti-anabolic action which has led to increased BUN, acidosis, hyperphosphatemia, azotemia, pancreatitis, and abnormal liver function tests, have been seen for other tetracycline-class antibacterial medicines, and may occur with Eravacycline. Discontinue this drug if any of these side effects are suspected.
• Eravacycline use may result in excess growth of non-susceptible organisms, including fungi. In case such infections emerge, discontinue therapy and institute apt therapy.
• Prescribing XERAVA (Eravacycline) in the absence of a firm or strongly suspected bacterial infection is unlikely to offer benefit to the patient and may increases the probability of the development of drug-resistant bacteria. 

What documents are required to import XERAVA to India?

XERAVA (Eravacycline) Injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity Proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is XERAVA available in India?

XERAVA (Eravacycline Injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

XERAVA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of XERAVA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable). 

Please contact +91-9310090915 | TOLL-FREE Number: 1800-889-1064 or write at info@indianpharmanetwork.in for Xerava 50 mg injection price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the XERAVA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network (IPN) offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Xerava®?

Eravacycline is Generic Name for the trade name drug Xerava®.

What is the Manufacturer Name of Xerava®?

Xerava® is manufactured by Tetraphase Pharmaceuticals, Inc.

Is Xerava® approved by the FDA?

Yes, Xerava® is approved by the FDA. Date of first/initial approval: August 27, 2018.

What is the dosage and form of Xerava® supplied?

Xerava® is supplied for injection: 50 mg of eravacycline (equivalent to 63.5 mg eravacycline dihydrochloride) as a lyophilized powder in a single-dose vial for reconstitution and further dilution for intravenous administration. 

Where can I get Xerava® at the best price in India?

To get the best Xerava price/cost in India, contact Indian Pharma Network (WHO-GDP & ISO 9001:2008 authorized Company). A valid medical prescription is required while buying Xerava®.

What are the most common side effects with Xerava®? 

The most common side effects with Xerava® include: nausea, infusion site reactions, and vomiting.

How much does Xerava® cost in India?

The cost of Xerava 50 mg injection in India is reasonable and can vary. In order to procure this antibacterial drug authentically, you can Call/WhatsApp: +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Xerava®?

Prior to reconstitution, this medicinal product should be stored at temperature 2°C to 8°C (36°F to 46°F). Keep the vials of Xerava® in a carton until use.

Is it safe to buy Xerava® online from India? 

Yes, You can buy Xerava 50 mg injection online from India at the best price from Indian Pharma Network if Xerava® has not been approved or is not available in your country. 

What are the Highlights of prescribing information for Xerava®?

Click Here to download full Xerava prescribing information.